Devalingam Mahalingam, MD, PhD ...

Dr. Devalingam Mahalingam, MBBChBAO

Claim this profile

Northwestern University

Studies Pancreatic Cancer
Studies Cancer
18 reported clinical trials
54 drugs studied

Area of expertise

1

Pancreatic Cancer

Devalingam Mahalingam, MBBChBAO has run 9 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
PTEN positive
PIK3CA positive
2

Cancer

Devalingam Mahalingam, MBBChBAO has run 8 trials for Cancer. Some of their research focus areas include:

Stage IV
PTEN positive
PIK3CA positive

Affiliated Hospitals

Image of trial facility.

Northwestern University

Image of trial facility.

Northwestern Medicine Cancer Center Kishwaukee

Clinical Trials Devalingam Mahalingam, MBBChBAO is currently running

Image of trial facility.

Pemetrexed

for Bladder Cancer

This phase II trial tests how well pemetrexed works in treating patients with urothelial bladder cancer and other solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) with mutations that result in a loss of function in the MLL4-protein/KMT2D-gene or UTX-protein/KDM6A-gene or MTAP enzyme. Loss of function due to a genetic mutation means a gene's activity may be reduced or eliminated. Mutations that result in a loss of function in the MLL4-protein or KMT2D-gene are found in 9.96% of all cancers including bladder carcinoma patients, esophageal squamous cell carcinoma and esophageal adenocarcinoma patients. In addition, mutations that result in a loss of function in the UTX-protein or KDM6A-gene are found in approximately 5% of all tumors, including bladder cancers, endometrial cancer, and esophagogastric cancer amongst many other tumor types. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Giving pemetrexed may increase response in patients with metastatic urothelial bladder cancer and other solid tumors with the loss of function in the MLL4-protein/KMT2D-gene or UTX-protein/KDM6A-gene or MTAP enzyme.

Recruiting

1 award

Phase 2

5 criteria

Image of trial facility.

²¹²Pb-DOTAM-GRPR1

for Cancer

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Recruiting

1 award

Phase 1

6 criteria

More about Devalingam Mahalingam, MBBChBAO

Clinical Trial Related

7 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 6 Active Clinical Trials

Treatments Devalingam Mahalingam, MBBChBAO has experience with

  • Hydroxychloroquine
  • Fluorouracil
  • Olaparib
  • Sotorasib
  • Binimetinib
  • Palbociclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Devalingam Mahalingam, MBBChBAO specialize in?

Is Devalingam Mahalingam, MBBChBAO currently recruiting for clinical trials?

Are there any treatments that Devalingam Mahalingam, MBBChBAO has studied deeply?

What is the best way to schedule an appointment with Devalingam Mahalingam, MBBChBAO?

What is the office address of Devalingam Mahalingam, MBBChBAO?

Is there any support for travel costs?